Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2872-2880

  Singh, Harjeet ^a,c   Serrano, Lisa Marie ^a   Pfeiffer, Timothy ^a   Olivares, Simon ^a,c   McNamara, George ^a   Smith, David D ^a   Al Kadhimi, Zaid ^a   Forman, Stephen J ^a   Gillies, Stephen D ^b   Jensen, Michael C ^a   Colcher, David ^a   Raubitschek, Andrew ^a   Cooper, Laurence J N ^a,c  

^a City of Hope National Medical Center   (United States)

^b EMD SERONO INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; MONOCLONAL ANTIBODY CD20 PLUS RECOMBINANT INTERLEUKIN 2; MONOCLONAL ANTIBODY GD2 DISIALOGANGLIOSIDE PLUS RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE TRANSFER; MONOTHERAPY; MOUSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; K562 CELLS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MICE; MICE, INBRED NOD; MICE, SCID; T-LYMPHOCYTES;

EID: 34047271156     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2283     Document Type: Article

References (50)

1. Stamenkovic I, Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 1988;168:1205-10.
2. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988;85:208-12.
3. Wortis HH. Surface markers, heavy chain sequences and B cell lineages. Int Rev Immunol 1992;8:235-46.
4. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74.
5. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385-97.
6. Weiner GJ, Link BK. Monoclonal antibody therapy of B cell lymphoma. Expert Opin Biol Ther 2004;4:375-85.
7. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279-86.
8. Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol 2005;129:322-32.
9. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676-84.
10. Roessig C, Scherer SP, Baer A, et al. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol 2002;81 Suppl 2:42-3.
11. Rossig C, Pscherer S, Landmeier S, Altvater B, Jurgens H, Vormoor J. Adoptive cellular immunotherapy with CD19-specific T cells. Klin Padiatr 2005;217:351-6.
12. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 1998;16:3691-710.
13. Schmitt CA, Schwaeble W, Wittig BM, Meyer zum Buschenfelde KH, Dippold WG. Expression and regulation by interferon-7 of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur J Cancer 1999;35:117-24.
14. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol 1999;26:97-106.
15. Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol 1999;106:827-32.
16. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
17. + T cells. Proc Natl Acad Sci U S A 2004;101:1969-74.
18. Minamoto S, Treisman J, Hankins WD, Sugamura K, Rosenberg SA. Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin- 2 receptors. Blood 1995;86:2281-7.
19. King DM, Albertini MR, Schalch H, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004;22:4463-73.
20. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 1998;80:277-92.
21. Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR. Preclinical and clinical development of immunocytokines. Curr Opin Investig Drugs 2003;4:696-700.
22. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood 2003;101:1637-44.
23. Serrano LM, Pfeiffer T, Olivares S, et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006;107:2643-52.
24. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.
25. Gillies SD, Lan Y, Williams S, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005;105:3972-8.
26. Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 1999;94:3551-8.
27. Farner NL, Voss SD, Leary TP, et al. Distinction between γc detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood 1995;86:4568-78.
28. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201.
29. Gillies SD, Reilly EB, Lo KM, Reisfeld RA, Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A 1992;89:1428-32.
30. Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005;105:1622-31.
31. Lupton SD, Brunton LL, Kalberg VA, Overell RW. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 1991;11:3374-8.
32. Rentsch B, Bucher U, Brun del Re GP. Biochemical identification of the antigen recognized by the monoclonal pan-B cell antibody Y29/55. Eur J Haematol 1991;47:204-12.
33. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24:263-71.
34. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-24.
35. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
36. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
37. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
38. Lode HN, Reisfeld RA. Targeted cytokines for cancer immunotherapy. Immunol Res 2000;21:279-88.
39. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001;248:91-101.
40. Jurcic JG, Scheinberg DA. Recent developments in the radioimmunotherapy of cancer. Curr Opin Immunol 1994;6:715-21.
41. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-36.
42. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1997;1333:1-6.
43. Chianese-Bullock KA, Woodson EM, Tao H, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005;28:412-9.
44. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
45. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
46. Gritzapis AD, Mamalaki A, Kretsovali A, et al. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer 2003;88:1292-300.
47. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A 1994;91:4318-22.
48. Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000;11:2377-87.
49. Haynes NM, Snook MB, Trapani JA, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs Fc epsilon RI-γ. J Immunol 2001;166:182-7.
50. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64:9160-6.